Syschem (India) (531173)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 81.97% shows strong top-line momentum
• Profit growth of 734% indicates sharp earnings acceleration
• Piotroski F-Score of 7/9 suggests improving fundamentals
• ROE of 14.53% is respectable for a small pharma company
• Latest quarter sales of ₹142 Cr are substantial relative to market cap of ₹165 Cr

Concerns

• ROCE of only 1.47% signals poor operating return on capital
• P/E of 25.78 and P/B of 3.09 leave little margin of safety
• Latest quarter net margin is very thin, roughly 2.8%
• No dividend and near 52-week low suggest weak investor returns despite headline growth

AI Analysis

When I look at Syschem, I see fast growth, but I must apply caution. A pharma business reporting sales up 82% and profit up 734% gets attention, but Graham taught me to value facts, not stories. The latest quarter shows sales of ₹142 Cr and net profit of ₹4 Cr, implying a thin net margin of roughly 2.8%. At a market cap of ₹165 Cr, today's earnings justify the price only if this growth continues. With a P/E of 25.78 and a P/B of 3.09, the market is already paying for good news. Book value of ₹13.35 gives only a modest cushion. ROE of 14.53% is respectable, but ROCE of 1.47% is alarming. That gap suggests operating returns are weak and the apparent equity return may be driven by leverage or one-off items. Without debt-to-equity or promoter holding data, I cannot assess balance sheet risk or whether management is aligned with minority shareholders. The Piotroski F-Score of 7/9 is decent, and a PEG of 0.06 looks inexpensive, but a PEG built on a 734% profit spike is meaningless if that growth is cyclical or non-recurring. The stock pays no dividend, so the investor depends entirely on price appreciation. It now trades near its 52-week low of ₹40.50, showing that momentum has reversed despite the headline numbers. In Buffett style, I prefer wonderful businesses at fair prices, and here I do not yet know if Syschem is wonderful. Low ROCE, thin margins, and unclear capital structure are serious red flags. I would wait for consistent margins, better return on capital, and cleaner financials before committing capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer